Shares of NewLink Genetics Corp. (NASDAQ:NLNK) traded down 1.9% on Thursday . The company traded as low as $11.32 and last traded at $11.36, with a volume of 88,445 shares changing hands. The stock had previously closed at $11.58.

A number of analysts have recently weighed in on the company. Zacks Investment Research upgraded NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Tuesday. Robert W. Baird restated a “buy” rating on shares of NewLink Genetics Corp. in a research note on Monday, May 16th. Jefferies Group reiterated a “hold” rating and issued a $10.00 price objective on shares of NewLink Genetics Corp. in a research report on Wednesday, May 11th. SunTrust Banks Inc. lowered NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $59.00 to $12.00 in a research report on Tuesday, May 10th. Finally, Mizuho lowered their price objective on NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.29.

The stock has a 50-day moving average price of $11.06 and a 200 day moving average price of $18.93. The company’s market cap is $335.36 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last released its earnings results on Friday, April 29th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.70) by $0.88. The company had revenue of $4.34 million for the quarter, compared to the consensus estimate of $2.08 million. On average, equities analysts expect that NewLink Genetics Corp. will post ($2.83) EPS for the current year.

Several hedge funds have made changes to their positions in the company. Cornerstone Capital Management Holdings LLC. increased its stake in shares of NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock valued at $1,993,000 after buying an additional 31,375 shares in the last quarter. GSA Capital Partners LLP increased its stake in shares of NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock valued at $2,386,000 after buying an additional 3,498 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock valued at $1,402,000 after buying an additional 636 shares in the last quarter. Russell Frank Co increased its stake in shares of NewLink Genetics Corp. by 57.1% in the fourth quarter. Russell Frank Co now owns 265,422 shares of the company’s stock valued at $9,712,000 after buying an additional 96,512 shares in the last quarter. Finally, EQIS Capital Management increased its stake in shares of NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock valued at $1,515,000 after buying an additional 35,587 shares in the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.